A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors
- DOI
- 10.1158/2767-9764.crc-26-0442
- Published
- 2026-10-29
- Container
- Cancer Research Communications
- Publisher
- American Association for Cancer Research (AACR)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1158/2767-9764.crc-26-0442,
title = {A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors},
author = {Markus Joerger and Nicolas Mach and Rahima Jamal and Anastasios Stathis and Steven F. Powell and Dagmar Hess and Andrey Loboda and Michael Lassman and Carolina Cabral and Chiara C. Kemal and Yao Chen and Yunlong Yang and Erik H. Knelson and Lillian L. Siu},
year = {2026},
journal = {Cancer Research Communications},
doi = {10.1158/2767-9764.crc-26-0442},
url = {https://doi.org/10.1158/2767-9764.crc-26-0442}
}RIS
TY - JOUR TI - A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors AU - Markus Joerger AU - Nicolas Mach AU - Rahima Jamal AU - Anastasios Stathis AU - Steven F. Powell AU - Dagmar Hess AU - Andrey Loboda AU - Michael Lassman AU - Carolina Cabral AU - Chiara C. Kemal AU - Yao Chen AU - Yunlong Yang AU - Erik H. Knelson AU - Lillian L. Siu PY - 2026 JO - Cancer Research Communications DO - 10.1158/2767-9764.crc-26-0442 UR - https://doi.org/10.1158/2767-9764.crc-26-0442 ER -
APA
Joerger, M., Mach, N., Jamal, R., Stathis, A., Powell, S. F., Hess, D., Loboda, A., Lassman, M., Cabral, C., Kemal, C. C., Chen, Y., Yang, Y., Knelson, E. H., & Siu, L. L. (2026). A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-26-0442
Source records
- crossref · retrieved 2026-11-10T16:49:02.084Z